David G. Alleva, Andrea R. Delpero, Thillainaygam Sathiyaseelan, Sylaja Murikipudi, T. Lancaster, Mark A. Atkinson, Clive Wasserfall, Liping Yu, Ramya Ragupathy, Rachel H. Bonami, Todd C. Zion,
... Methods/Results To target insulin-reactive B cells, AKS-107, a human IgG1 Fc molecule fused with human ... but prevented binding to the insulin metabolic receptor. AKS-107 Fc-mediated deletion of insulin-reactive B cells ... 23) dominant T cell epitope was engineered into AKS-107 to suppress activation of insulin-specific T cells. In mice and non-human primates, AKS-107 was well-tolerated, non-immunogenic, did not cause ... doses, and showed an expectedly protracted pharmacokinetic profile. AKS-107 reproducibly prevented spontaneous diabetes from developing in NOD ...
Tópico(s): Diabetes Management and Research
2024 - Frontiers Media | Frontiers in Immunology